US equities
|
NVDA
$234.37
▲+1.52%
MU
$1,074.88
▼-2.05%
SPCX
$159.15
▲+7.48%
TSLA
$372.62
▲+5.23%
SNDK
$1,721.68
▼-3.69%
STX
$838.18
▼-11.36%
AMD
$632.48
▲+2.72%
INTC
$119.81
▼-0.16%
NVDA
$234.37
▲+1.52%
MU
$1,074.88
▼-2.05%
SPCX
$159.15
▲+7.48%
TSLA
$372.62
▲+5.23%
SNDK
$1,721.68
▼-3.69%
STX
$838.18
▼-11.36%
AMD
$632.48
▲+2.72%
INTC
$119.81
▼-0.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Aulos Bioscience
Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting
Today 9:05 EDT
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
May 21, 2026
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting
April 21, 2026
From
Aulos Bioscience
Via
Business Wire
New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer
November 07, 2025
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 03, 2025
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting
April 29, 2025
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
April 14, 2025
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting
March 25, 2025
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
November 27, 2024
From
Aulos Bioscience
Via
Business Wire
Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 23, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 09, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 04, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
May 23, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007
May 15, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
April 24, 2024
From
Aulos Bioscience
Via
Business Wire
First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers
January 25, 2024
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors
December 18, 2023
From
Aulos Bioscience
Via
Business Wire
New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2023
From
Aulos Bioscience
Via
Business Wire
New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2023
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 27, 2023
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners
August 01, 2023
From
Aulos Bioscience
Via
Business Wire
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells
May 25, 2023
From
Aulos Bioscience
Via
Business Wire
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
February 01, 2023
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors
October 31, 2022
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 11, 2022
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
May 26, 2022
From
Aulos Bioscience
Via
Business Wire
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
May 05, 2022
From
Aulos Bioscience
Via
Business Wire
